New immunotherapy combo shows promise for tough lung cancer
NCT ID NCT04063163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested whether adding an experimental immunotherapy drug called HLX10 to standard chemotherapy could help people with extensive-stage small cell lung cancer live longer. The study enrolled 585 people who had not received prior treatment. Participants were randomly assigned to receive either HLX10 plus chemo or a placebo plus chemo. The main goal was to see if the combination improved overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX10 (a PD-1 inhibitor) combined with chemotherapy (carboplatin and etoposide)
What this could lead to
If successful, this combination could become a new first-line treatment option for extensive-stage small cell lung cancer, potentially improving survival.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. Adding immunotherapy to chemo may increase side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkhangelsk Clinical Oncology Dispensary
Arkhangelsk, Russia
-
Institute for Personalized Medicine
Tbilisi, Georgia
-
Komunalnyi zaklad Miska bahato
Dnipropetrovsk, Ukraine
-
Medipol Mega Hospital
Istanbul, Turkey (Türkiye)
-
Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi
Lodz, Poland